All PlansCoverageMedium impact
Investigational Gene Expression, Biomarker, and Multianalyte Testing
Regence BlueShield·Oncology, Neurology, Cardiology +5 more·Coding
Effective date
Apr 1, 2026
We identified it
Jun 16, 2026
Summary
A comprehensive list of investigational gene expression, biomarker, and multianalyte tests that are not covered by insurance and considered experimental. These tests will be denied for reimbursement, and providers may bill patients directly for these services.
Action Required
By April 1, 2026: Billing team must update system to flag all listed investigational tests as non-covered services requiring patient financial responsibility. Update encounter forms and billing software to prevent automatic insurance billing for these tests. Ensure providers inform patients before rendering services that they will be financially responsible for costs.